文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

低剂量红霉素对脓毒症危重患者死亡率及宿主反应的影响:一项目标试验模拟研究

Effect of erythromycin on mortality and the host response in critically ill patients with sepsis: a target trial emulation.
PubMed 文献 · Crit Care · 2022-05-24
一句话结论在脓毒症危重患者中,低剂量红霉素(作为促动力药使用)未能降低90天死亡率,也未改善次要临床结局或宿主反应生物标志物。

该目标试验模拟研究纳入荷兰两个ICU中住院至少72小时的脓毒症患者,比较暴露于低剂量红霉素(每日最多600 mg,作为促动力药使用)且未使用其他大环内酯类药物的患者与未暴露患者的结局。采用倾向评分匹配和逆概率加权处理适应证混杂,Cox回归估计90天死亡率效应。结果共235例接受低剂量红霉素、470例对照;匹配HR 0.89(95%CI 0.64-1.24),加权HR 0.95(95%CI 0.66-1.36),90天死亡率无差异;次要临床结局及15种宿主反应生物标志物从入ICU至第4天的变化也无差异。

要点

  • 在脓毒症危重患者中,低剂量红霉素(每日最多600 mg,作为促动力药)与对照相比,90天死亡率无差异:匹配HR 0.89(95%CI 0.64-1.24),加权HR 0.95(95%CI 0.66-1.36)。
  • 红霉素组与对照组在次要临床结局(SOFA变化、机械通气时长、ICU获得性感染发生率)上无差异。
  • 15种反映关键病理生理过程的宿主反应生物标志物从入ICU至第4天的变化在两组间相似。
  • 红霉素治疗在入ICU后中位38小时(IQR 25-52)开始,首个疗程中位总剂量为5次(IQR 3-8)。
  • 该研究为在荷兰两个ICU进行的目标试验模拟,采用倾向评分匹配和逆概率加权处理混杂。

适用人群与场景

  • 荷兰两个ICU中住院至少72小时的脓毒症成人患者。
  • 暴露组为期间接受低剂量红霉素(每日最多600 mg,作为促动力药使用)且未使用其他大环内酯类药物的患者;对照组为未暴露于红霉素的患者。

处置流程与药物剂量

  • 低剂量红霉素用法:每日最多600 mg,作为促动力药给药,治疗在入ICU后中位38小时(IQR 25-52)开始,首个疗程中位总剂量为5次(IQR 3-8)。

研究设计与关键结果

  • 研究设计:目标试验模拟,纳入荷兰两个ICU中住院至少72小时的脓毒症患者,比较低剂量红霉素暴露(235例)与未暴露对照(470例)。
  • 主要结局:90天死亡率,匹配HR 0.89(95%CI 0.64-1.24),加权HR 0.95(95%CI 0.66-1.36),两组无差异。
  • 次要临床结局:SOFA变化、机械通气时长、ICU获得性感染发生率在两组间无差异。
  • 宿主反应:15种生物标志物从入ICU至第4天的变化在红霉素组与对照组间相似。
  • 治疗特征:红霉素在入ICU后中位38小时(IQR 25-52)开始,首个疗程中位总剂量为5次(IQR 3-8)。

证据类型、等级与局限

  • 证据类型:目标试验模拟(target trial emulation),采用倾向评分匹配和逆概率加权处理混杂,Cox回归估计效应。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于脓毒症危重患者,低剂量红霉素(每日最多600 mg,作为促动力药)未能降低90天死亡率,也未改善次要临床结局或宿主反应生物标志物。
  • 作者结论:在该目标试验模拟中,未能证明低剂量红霉素对死亡率、次要临床结局或宿主反应生物标志物有影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Immunomodulatory therapies that improve the outcome of sepsis are not available. We sought to determine whether treatment of critically ill patients with sepsis with low-dose erythromycin-a macrolide antibiotic with broad immunomodulatory effects-decreased mortality and ameliorated underlying disease pathophysiology.

METHODS: We conducted a target trial emulation, comparing patients with sepsis admitted to two intensive care units (ICU) in the Netherlands for at least 72 h, who were either exposed or not exposed during this period to treatment with low-dose erythromycin (up to 600 mg per day, administered as a prokinetic agent) but no other macrolides. We used two common propensity score methods (matching and inverse probability of treatment weighting) to deal with confounding by indication and subsequently used Cox regression models to estimate the treatment effect on the primary outcome of mortality rate up to day 90. Secondary clinical outcomes included change in SOFA, duration of mechanical ventilation and the incidence of ICU-acquired infections. We used linear mixed models to assess differences in 15 host response biomarkers reflective of key pathophysiological processes from admission to day 4.

RESULTS: In total, 235 patients started low-dose erythromycin treatment, 470 patients served as controls. Treatment started at a median of 38 [IQR 25-52] hours after ICU admission for a median of 5 [IQR 3-8] total doses in the first course. Matching and weighting resulted in populations well balanced for proposed confounders. We found no differences between patients treated with low-dose erythromycin and control subjects in mortality rate up to day 90: matching HR 0.89 (95% CI 0.64-1.24), weighting HR 0.95 (95% CI 0.66-1.36). There were no differences in secondary clinical outcomes. The change in host response biomarker levels from admission to day 4 was similar between erythromycin-treated and control subjects.

CONCLUSION: In this target trial emulation in critically ill patients with sepsis, we could not demonstrate an effect of treatment with low-dose erythromycin on mortality, secondary clinical outcomes or host response biomarkers.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Reijnders TDY, Peters-Sengers H, van Vught LA, et al. Effect of erythromycin on mortality and the host response in critically ill patients with sepsis: a target trial emulation. Crit Care. 2022. PMID: 35610649. doi:10.1186/s13054-022-04016-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。